Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

Rhea-AI Summary

Protara Therapeutics (Nasdaq:TARA) will host a virtual investor webinar at 4:30 pm ET on Tuesday, May 19, 2026.

The event will cover lymphatic malformations, current treatment landscape, market opportunity and regulatory path for TARA-002, plus clinical data supporting its use. Access is via the company’s investor relations website, with a replay available for a limited time.

AI-generated analysis. Not financial advice.

News Market Reaction – TARA

-9.80%

20 alerts

-9.80% News Effect

-4.5% Trough in 2 hr 32 min

-$29M Valuation Impact

$264.74M Market Cap

1.0x Rel. Volume

On the day this news was published, TARA declined 9.80%, reflecting a notable negative market reaction. Argus tracked a trough of -4.5% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $29M from the company's valuation, bringing the market cap to $264.74M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cash & equivalents: $177.4M Quarterly net loss: $17.8M Shelf registration size: $300,000,000 +5 more

8 metrics

Cash & equivalents $177.4M Unrestricted cash, cash equivalents and marketable debt securities as of Mar 31, 2026

Quarterly net loss $17.8M Net loss for three months ended Mar 31, 2026 vs $11.9M prior year

Shelf registration size $300,000,000 Maximum aggregate offering amount under S-3 shelf filed May 13, 2026

Janus Henderson stake 5,207,011 shares (9.6%) Beneficial ownership reported in Schedule 13G/A

Shares outstanding 55,060,500 Common shares entitled to vote as of Apr 15, 2026

CR rate BCG-unresponsive 68.2% Six‑month complete response in ADVANCED‑2 BCG‑unresponsive cohort as of Jan 28, 2026

CR rate BCG-naïve 66.7% Six‑month complete response in ADVANCED‑2 BCG‑naïve cohort as of Jan 28, 2026

Any-time CR BCG-naïve 72.4% Any‑time complete response in ADVANCED‑2 BCG‑naïve cohort

Market Reality Check

Price: $4.65 Vol: Volume 1,122,887 vs 20-da...

high vol

$4.65 Last Close

Volume Volume 1,122,887 vs 20-day average 659,676 (relative volume 1.7x) ahead of the webinar. high

Technical Shares at $5.10, trading just below the 200-day MA of $5.13 and 34.78% under the $7.82 52-week high.

Peers on Argus

TARA fell 3.77% while momentum-screened biotech peers INO, EQ and CRBP each move...

3 Up

TARA fell 3.77% while momentum-screened biotech peers INO, EQ and CRBP each moved up over 3%, indicating today’s weakness looks more stock-specific than sector-driven.

Historical Context

5 past events · Latest: May 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 13	Earnings and update	Positive	+1.0%	Q1 2026 results and pipeline plans, including TARA-002 BLA timing.
Apr 27	Clinical data update	Positive	+1.4%	Announcement of updated 12‑month Phase 2 ADVANCED‑2 data presentation.
Mar 10	Earnings and data	Positive	-0.7%	Full‑year 2025 results and interim TARA‑002 CR rates with strong cash position.
Feb 23	Clinical results	Positive	-26.4%	Interim Phase 2 ADVANCED‑2 NMIBC data with high complete response rates.
Feb 19	Investor conferences	Neutral	+7.2%	Participation in late‑Feb and early‑Mar healthcare investor conferences.

Pattern Detected

Recent fundamentally positive updates on TARA-002 sometimes coincided with negative price moves, suggesting occasional sell-the-news dynamics.

Recent Company History

Over the last few months, Protara has reported several key milestones. On Feb 23 (news_id 1017010), strong Phase 2 ADVANCED-2 data in NMIBC showed six‑month CR rates of 68.2% and any‑time CR of 72.4%, yet shares fell 26.38%. Earnings updates on Mar 10 and May 13 highlighted cash of $177.4M and plans for a TARA‑002 BLA in LMs in 2H 2027, with modest price reactions. Conference and data-presentation announcements have generally produced small gains, framing today’s LM-focused webinar as part of an ongoing investor-education outreach.

Regulatory & Risk Context

Active S-3 Shelf · $300,000,000

Shelf Active

Active S-3 Shelf Registration 2026-05-13

$300,000,000 registered capacity

An effective S-3 shelf filed on May 13, 2026 allows Protara to offer up to $300,000,000 in common stock, preferred stock, debt securities and/or warrants, including $110,914,137.87 of unsold securities from a prior registration, with proceeds designated for general corporate purposes such as R&D, clinical trials and working capital.

Market Pulse Summary

The stock moved -9.8% in the session following this news. A negative reaction despite an information...

Analysis

The stock moved -9.8% in the session following this news. A negative reaction despite an informational webinar announcement fits prior instances where positive TARA‑002 updates coincided with selling, such as the 26.38% drop after strong ADVANCED‑2 data. The backdrop includes a wider quarterly net loss of $17.8M and a newly filed $300,000,000 shelf registration, which may heighten sensitivity to dilution and funding risk, even when the news focus is education on lymphatic malformations.

Key Terms

lymphatic malformations, non-muscle invasive bladder cancer, bcg-naïve, bcg-unresponsive, +4 more

8 terms

lymphatic malformations medical

"The agenda will include an overview of Lymphatic Malformations (LMs)..."

Lymphatic malformations are abnormal clusters or sacs formed when the body’s lymphatic “plumbing” (the vessels that drain fluid and fight infection) grows or connects incorrectly, often causing swelling, pain, infection risk or breathing and feeding problems. Investors watch them because they create demand for specialized treatments, procedures and long-term care, influence clinical trial designs and regulatory reviews, and can affect reimbursement and market potential for drugs, devices or therapies targeting these conditions.

non-muscle invasive bladder cancer medical

"TARA-002 for non-muscle invasive bladder cancer with promising complete response rates..."

A form of bladder cancer that is confined to the inner lining of the bladder and has not grown into the deeper muscle layer; think of it like a stain on wallpaper rather than damage to the wall’s studs. It matters to investors because it has different treatment, monitoring and recurrence patterns than deeper cancers, driving demand for repeated outpatient procedures, local therapies and diagnostic tests that affect revenue, trial design and pricing dynamics in healthcare markets.

bcg-naïve medical

"Phase 2 ADVANCED-2 trial of TARA-002 in BCG‑naïve NMIBC patients..."

BCG-naïve describes patients who have never received Bacillus Calmette–Guérin (BCG) therapy, a common first-line immunotherapy for certain bladder cancers. For investors, this matters because drugs or devices tested or approved for BCG-naïve patients address a different group and potential market size than treatments for those who already failed BCG; think of it like a product aimed at first-time buyers versus repeat customers.

bcg-unresponsive medical

"BCG-Unresponsive cohort six-month CR 68.2% (15/22)..."

BCG-unresponsive describes a situation in which a patient’s bladder cancer does not shrink or returns despite receiving an adequate course of BCG, a common vaccine-based intravesical treatment used to stimulate the immune system in the bladder. For investors this matters because it defines a group of patients who need alternative therapies or procedures, shaping clinical trial eligibility, regulatory pathways, and the potential market for new drugs; think of it like weeds that resist the usual weed killer and require a different product.

biologics license application regulatory

"plans to submit a Biologics License Application for TARA‑002 in lymphatic malformations..."

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

phase 2 medical

"Phase 2 ADVANCED-2 trial of TARA-002 in BCG‑naïve NMIBC patients..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

phase 3 medical

"initiated the registrational THRIVE-3 Phase 3 trial for IV Choline Chloride..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

shelf registration statement regulatory

"[S-3] Protara Therapeutics, Inc. Shelf Registration Statement"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

AI-generated analysis. Not financial advice.

Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program

NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a virtual webinar for the investment community at 4:30 pm ET on Tuesday, May 19, 2026. The agenda will include an overview of Lymphatic Malformations (LMs), key opinion leader (KOL) perspectives on the burden of disease and current treatment landscape, the market opportunity and regulatory path for TARA-002 and a review of clinical data supporting the use of TARA-002 in LMs.

The live event and accompanying slides can be accessed visiting the Events and Presentations section of the Company’s website https://ir.protaratx.com. A replay of the webcast will be archived for a limited time following the event.

About TARA-002

TARA-002 is an investigational cell therapy in development for the treatment of NMIBC and of LMs, for which it has been granted Rare Pediatric Disease, Orphan Drug, Breakthrough Therapy and Fast Track designations by the FDA. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes with a mechanism of action that includes the activation of innate and adaptive immune pathways. When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a pro-inflammatory response with the release of cytokines such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, IL-6, IL-10 and IL-12. TARA-002 also directly kills tumor cells and triggers a host immune response by inducing immunogenic cell death, which further enhances the antitumor immune response.

TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil® in Japan by Chugai Pharmaceutical Co., Ltd.

About Lymphatic Malformations

Lymphatic Malformations (LMs) are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Protara’s focus is on macrocystic and mixed cystic LMs, for which there are no currently approved therapies. They are most frequently present in the head and neck region and are diagnosed in early childhood during the period of active lymphatic growth, with more than 50% detected at birth and 90% diagnosed before the age of three years. The most common morbidities and serious manifestations of the disease include compression of the upper aerodigestive tract, including airway obstruction requiring intubation and possible tracheostomy dependence; intralesional bleeding; impingement on critical structures, including nerves, vessels and lymphatics; recurrent infection; and cosmetic and other functional disabilities. TARA-002 has been granted Rare Pediatric Disease, Orphan Drug, Breakthrough Therapy and Fast Track designations by the FDA for the treatment of LMs.

About Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a pivotal Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com 
646-817-2836

FAQ

When is Protara Therapeutics (TARA) hosting its TARA-002 lymphatic malformations investor webinar?

Protara Therapeutics is hosting the TARA-002 investor webinar on Tuesday, May 19, 2026, at 4:30 pm ET. According to Protara, the virtual event targets the investment community and will review disease background, treatment landscape, and clinical data in lymphatic malformations.

How can investors access Protara Therapeutics' May 19, 2026 TARA-002 webinar?

Investors can access Protara’s TARA-002 webinar via the Events and Presentations section of its investor relations website. According to Protara, the live webcast and accompanying slides will be available online, with a replay archived for a limited time after the event.

What topics will Protara (TARA) cover about TARA-002 for lymphatic malformations in the 2026 webinar?

The webinar will cover lymphatic malformations, current treatment options, and TARA-002’s clinical program. According to Protara, the agenda includes KOL perspectives, market opportunity, regulatory path for TARA-002, and a review of clinical data supporting its potential use in lymphatic malformations.

Will Protara Therapeutics share clinical data on TARA-002 for lymphatic malformations during the May 2026 event?

Yes, Protara plans to review clinical data supporting TARA-002 in lymphatic malformations during the webinar. According to Protara, this data review will complement discussions on disease burden, treatment landscape, market opportunity, and regulatory considerations for the TARA-002 program.

Who is the target audience for Protara Therapeutics' May 19, 2026 TARA-002 webinar?

The primary audience is the investment community interested in Protara’s TARA-002 lymphatic malformations program. According to Protara, the virtual webinar will provide investors with expert KOL insights, market context, and clinical and regulatory information relevant to TARA-002’s development.

Will a replay of Protara (TARA) TARA-002 lymphatic malformations webinar be available to investors?

Yes, a replay of the TARA-002 lymphatic malformations webinar will be archived for a limited time. According to Protara, investors can access the replay and slides through the Events and Presentations section of the company’s investor relations website after the live event.